Moneycontrol
you are here: HomeNewsBusiness
Last Updated : Jan 03, 2019 07:52 PM IST | Source: Reuters

Drugmaker Bristol-Myers to buy Celgene for $74 billion

Celgene shareholders will receive one Bristol-Myers Squibb share and $50 in cash for each share held, or $102.43 per share, a premium of 53.7 percent to Celgene's closing on January 2.

Bristol-Myers Squibb said on January 3 it would buy Celgene Corp for about $74 billion in a cash-and-stock deal, creating a powerhouse that will have several blockbuster cancer drugs.

The combined company will have nine products with more than $1 billion in annual sales and significant potential for growth in oncology, immunology and inflammation and cardiovascular disease.

Celgene shareholders will receive one Bristol-Myers Squibb share and $50 in cash for each share held, or $102.43 per share, a premium of 53.7 percent to Celgene's closing on January 2.

Celgene shareholders will also receive one tradeable contingent value right for each share held, which will entitle them to payments for future regulatory milestones.

Bristol-Myers shares fell 13 percent at $45.20, while Celgene shares rose 30.5 percent at $87 in premarket trading.

The cash portion will be funded through a combination of cash on hand and debt financing. Bristol-Myers Squibb has obtained fully committed debt financing from Morgan Stanley Senior Funding Inc and MUFG Bank.
First Published on Jan 3, 2019 07:41 pm
More From
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant